Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 5/20 | 0.73 |
| ▸ | GSK3B | P49841 | 5/20 | 0.73 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.73 |
| ▸ | CDK1 | P06493 | 1/20 | 0.73 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.73 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.73 |
| ▸ | RGS4 | P49798 | 14/20 | 0.67 |
| ▸ | RGS8 | P57771 | 13/20 | 0.67 |
| ▸ | RGS16 | O15492 | 1/20 | 0.58 |
| ▸ | RGS19 | P49795 | 1/20 | 0.58 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023665 | 0.86 | GSK3B (0.73) | GSK3AGSK3BCCNB2CDK1CCNB1 | |
| SCHEMBL18802339 | 0.85 | GSK3B (0.71) | GSK3AGSK3BCCNB2CDK1CCNB1 | |
| SCHEMBL6429448 | 0.85 | GSK3B (0.71) | GSK3AGSK3BCCNB2CDK1CCNB1 | |
| SCHEMBL139834 | 0.84 | GSK3B (1.00) | GSK3AGSK3BCCNB2CDK1CCNB1 | |
| SCHEMBL13517889 | 0.83 | RGS4 (0.88) | GSK3AGSK3BCCNB2CDK1CCNB1 | |
| SCHEMBL6427057 | 0.81 | GSK3A (0.65) | GSK3AGSK3BCCNB2CDK1CCNB1 | |
| SCHEMBL13516931 | 0.80 | RGS4 (1.00) | RGS4RGS8RGS16RGS19 | |
| SCHEMBL29239064 | 0.80 | RGS4 (0.75) | GSK3AGSK3BRGS4RGS8RGS16 | |
| SCHEMBL13517418 | 0.78 | RGS4 (0.78) | GSK3AGSK3BCCNB2CDK1CCNB1 | |
| SCHEMBL2107221 | 0.78 | RGS4 (1.00) | GSK3AGSK3BCCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10029997-B2 | Compositions and methods for treating cancers | CEDARS-SINAI MEDICAL CENTER (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170121297-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | CEDARS-SINAI MEDICAL CENTER (US) | 2017-05-04 | — | — | US | disclosed |
| WO-2012065065-A9 | METHODS AND COMPOSITIONS FOR MODULATING HAIR GROWTH, WOUND HEALING AND SCAR REVISION | FOLLICA, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012065065-A1 | METHODS AND COMPOSITIONS FOR MODULATING HAIR GROWTH, WOUND HEALING AND SCAR REVISION | FOLLICA, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121297-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | GSK3B, HDAC1, HDAC3 | GSK3A 4/4885GSK3B 1/4885CCNB2 2237/4885 |
| US-10029997-B2 | Compositions and methods for treating cancers | HDAC3, HDAC1, GSK3B | GSK3A 7/4885GSK3B 3/4885CCNB2 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.